Vilobelimab (CaCP-29, IFX-1) is a monoclonal antibody specifically targeting C5a, a potent pro-inflammatory peptide derived from the complement system. By binding to C5a, Vilobelimab effectively inhibits its interaction with the C5a receptor, thereby attenuating neutrophil activation and chemotaxis. This inhibition plays a crucial role in reducing inflammatory signaling pathways associated with severe clinical conditions such as organ dysfunction. Vilobelimab is highly relevant for research in pathological states where the complement cascade contributes to disease progression, including sepsis and COVID-19.
Vilobelimab (CaCP-29, IFX-1) is a monoclonal antibody specifically targeting C5a, a potent pro-inflammatory peptide derived from the complement system. By binding to C5a, Vilobelimab effectively inhibits its interaction with the C5a receptor, thereby attenuating neutrophil activation and chemotaxis. This inhibition plays a crucial role in reducing inflammatory signaling pathways associated with severe clinical conditions such as organ dysfunction. Vilobelimab is highly relevant for research in pathological states where the complement cascade contributes to disease progression, including sepsis and COVID-19.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
